Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Millennium Pharmaceuticals, Inc. (MLNM) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (2711)	9/28/2006 5:45:25 PM
From: Icebrg	Respond to of 3044

Millennium Pharmaceuticals "underweight" Thursday, September 28, 2006 3:48:21 AM ET Prudential Financial NEW YORK, September 28 (newratings.com) - Analyst Ron Ellis of Prudential Financial maintains his "underweight" rating on Millennium Pharmaceuticals (MLNM.NAS). The target price is set to $10. In a research note published yesterday, the analyst mentions that Millennium Pharmaceuticals is acquiring AnorMed for $515 million or $12 per share, representing a 21% premium to the latter company's closing price. The analyst expresses his concern regarding Millennium Pharmaceuticals’ ability to properly leverage AnorMed's Mozobil product, which is scheduled to be launched in the US in 2008. The acquisition is expected to be dilutive to the company's finances and profitability, the analyst adds.